Fig. 4

TESC is a potential novel oncogene. a, b Declining cell growth in AGS (a) and HT29 (b) cells after TESC silencing. The absorbance value of the controls at day 1 was arbitrarily set at 100 %. *P <0.05: compared with the control and NC. c Images of metastatic tumor cells in TESC-silenced cells. The migratory ability of two siTESCs-treated AGS and HT29 tumor cells were significantly decreased. The migration assay was conducted 48 h after transfection with siTESCs or control siRNA. d, e Soft agar colony assay showing the ability of tumor formation in vitro. A tiny colony observed in whole-well testing (d) and under the microscope (e). Bars: 100 μm. Arrow: tumor colony. f RT-PCR showing the high expression of TESC in a variety of tumor cells. TESC was abundant in tumor cells but not in fibroblasts. g ROR and TESC expressionl evels in normal tissues, colon cancer, and melanoma tissues. Both TESC and ROR were highly expressed in colon cancer and melanoma tissues compared with that of normal tissues. The expression of TESC was increased with the level of ROR in tumors. h Immunohistochemical staining of TESC in tumor and normal tissues. TESC expression in tumor sections from five colon cancer patients and five melanoma patients was higher than normal tissues (original magnification, 200×)